Intravacc, Versatope to develop universal flu vaccine

By The Science Advisory Board staff writers

June 8, 2020 -- Dutch vaccine developer Intravacc and biotechnology firm Versatope have signed an agreement to collaborate on a universal influenza vaccine.

Intravacc will support Lowell, MA-based Versatope in bringing its universal influenza vaccine candidate VT-105 to clinical trial; the vaccine will include Intravacc's outer membrane vesicles (OMV) technology, the two companies said.

The companies hope that the OMV technology will provide better cross-strain protection than other influenza vaccines that consist of individual strains.

Intravacc forms public-private partnership for intranasal COVID-19 vaccine
Intravacc announced that it is partnering with Wageningen Bioveterinary Research and Utrecht University for the development of an intranasal vaccine against...
Intravacc, EpiVax partner for COVID-19 vaccine
Intravacc and EpiVax have entered a collaborative agreement to further develop a novel vaccine against COVID-19 based on Intravacc's proprietary outer...
Universal flu vaccine R&D collaboration established
Clinical-stage biopharmaceutical company TFF Pharmaceuticals has partnered with researchers at the University of Georgia and University of Texas to evaluate...
Better flu treatments on the way thanks to the discovery of broadly protective antibodies
Research from the National Institutes of Allergy and Infectious Diseases (NIAID) isolated the antibodies from a person sick with the flu five days after...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter